Metabolic Peptides
Retatrutide
Triple incretin agonist RUO peptide with HPLC/MS identity confirmation. Public sequence literature; batch COA on request. Not for human use.
Select Dosage
Retatrutide (39-mer triple GLP-1/GIP/glucagon agonist) is supplied as lyophilized powder in sterile glass vials. Structure is described in public patent and trial literature (e.g. US11542313B2); independent synthesis requires lot-specific HPLC and mass spectrometry — which we provide on request. Strictly for qualified in-vitro and preclinical research under institutional oversight. Not Lilly investigational product; not for injection, weight management, or veterinary use.
Quality & Manufacturing

Third-Party Mass Spectrometry Verified
Every production batch undergoes independent HPLC and mass spectrometry analysis. Certificates of Analysis (COA) are available upon request, documenting peptide identity, purity ≥ 99%, and absence of contaminants.
- HPLC purity ≥ 99.0% on every batch
- MS identity confirmation included
- Endotoxin testing for sterile-grade products
- COA available per lot number
Retatrutide research specifications
| Material format | Lyophilized research material |
|---|---|
| Identity / purity review | HPLC documentation; MS where specified |
| Batch documentation | Lot-specific COA available for qualified procurement |
| Intended use | Research Use Only (RUO), not for human or veterinary use |
Research FAQ
What documentation is available for Retatrutide?
Batch-level HPLC identity documentation and a certificate of analysis are available for qualified laboratory procurement.
How is Retatrutide supplied for laboratory research?
The material is supplied as lyophilized research material with the package and variant details shown above.
Is Retatrutide intended for human or veterinary use?
No. This product is strictly Research Use Only and is not intended for human or veterinary use.